Blue, if the combo data is good, it could be a game changer. My understanding was some preliminary data could have been available by last December. I would like to see a teaser of it released before ASCO. I was not aware of the changes to the NEO trial and I assume they are for the best if Amgen is on board. I suspect we may hear more about it at the annual meeting.
News 
Market Data 
Discover 
